The World Health Organization (WHO) on Tuesday said the Technical Advisory Group (TAG) for Emergency Use Listing (EUL) has decided that additional clarifications from Hyderabad-based Bharat Biotech are requisite to conduct a final EUL risk-benefit assessment for global use and acknowledgement of Covaxin.
WHO clearance is an imperative step in Covaxin being accepted by foreign governments. EUL is important to remove precariousness around overseas travel by Indians inoculated with this vaccine.
The Technical Advisory Group for Emergency Use Listing (TAG-EUL) is an independent advisory group that provides recommendations to WHO on whether a Covid-19 vaccine can be listed for emergency use under the EUL procedure. As a matter of fact, the TAG met on Tuesday (26 October 2021) and decided that additional clarifications from the manufacturer are required to conduct a final EUL risk-benefit analysis for global use of the vaccine,” WHO told The Indian Express.